Suppr超能文献

特发性膜性肾病老年患者的临床病理特征及预后。

Clinicopathological features and outcome in elderly patients with idiopathic membranous nephropathy.

机构信息

Department of Geriatric Nephrology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangdong Provincial Geriatrics Institute, Guangzhou, China.

The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.

出版信息

Ren Fail. 2023 Dec;45(1):2212081. doi: 10.1080/0886022X.2023.2212081.

Abstract

BACKGROUND

Idiopathic membranous nephropathy (IMN) is the leading cause of nephrotic syndrome in the elderly. The treatment of idiopathic membranous nephropathy is quite challenging due to the particularity of elderly patients. This study intends to investigate the clinicopathological characteristics and initial therapeutic effect of idiopathic membranous nephropathy among elderly patients.

METHODS

A retrospective study of 67 elderly patients (58.2% male, median age 69.0 years, range, 65-83 years) with biopsy-proven membranous nephropathy was conducted at Guangdong Provincial People's Hospital from 2016 to 2020. Data on clinicopathological characteristics and initial therapeutic effects were analyzed.

RESULTS

Of the 67 patients, the mean eGFR of overall patients was 66.49 mL/min/1.73m while the median urine protein-to-creatinine ratio (uPCR) and urine albumin-to-creatinine ratio (uACR) was 5676.73 mg/g and 2951.56 mg/g, respectively. Pathological data revealed that the membranous Churg's stage II was the most frequent (71.64%). Moreover, glomerular PLA2R antigen fluorescence intensity of (+) and IgG4 antigen fluorescence intensity of (++) were detected in 63.6% and 86.4% of all patients, respectively. Overall, 44 patients, accounting for 65.7%, achieved remission including complete remission and partial remission within 1 year after renal biopsy. Compared with a non-remission group, the levels of uPCR (6274.6 vs. 3235.6 mg/g,  = 0.007) and uACR (3433.6 vs. 1773.2 mg/g,  = 0.017) were significantly higher in remission group. The proportion of immunosuppressive therapy in the remission group was also higher (86.4% vs. 30.4%,  < 0.01). Compared with conservative treatment, patients with combined treatment with glucocorticoid and cyclophosphamide (CTX) or glucocorticoid and calcineurin inhibitor (CNIs) achieved higher remission rate (glucocorticoid plus cyclophosphamide vs. conservative treatment, 84.6% vs. 27.3%,  = 0.001; glucocorticoid plus calcineurin inhibitor vs. conservative treatment, 88.0% vs. 27.3%,  < 0.001). Further analysis showed that compared with patients who underwent conservative treatment, the proportion of males, the levels of uPCR, uACR, BUN, Scr, CysC and PLA2R antigen-positive staining rate in kidney biopsy were higher in those who underwent combined treatment with glucocorticoid and CTX, while the levels of eGFR, TP and ALB were lower ( < 0.05). In addition, patients who received combined treatment with glucocorticoid and CNIs had higher levels of uPCR, uACR, TC and lower levels of TP, ALB than those who received conservative treatment ( < 0.05). Moreover, there were no statistically significant differences in the 1-year progression rate in eGFR between the immunosuppressive treatment group and conservative treatment group (3.3 vs. 0.2 ml/min/1.73m,  = 0.852).

CONCLUSIONS

Most elderly patients diagnosed with IMN had multiple comorbidities, and the membranous Churg's stage II was most common. The glomerular PLA2R and IgG4 antigen deposition were frequently detected accompanied by glomerulosclerosis and severe tubulointerstitial injury. For high-risk elderly patients with severe proteinuria, early initial immunosuppressive therapy could achieve a higher urinary protein remission rate. Therefore, it is crucial for clinicians to balance the risks and benefits of immunosuppressive therapy based on clinical and pathological characteristics and develop individualized treatment regimens for elderly patients with IMN.

摘要

背景

特发性膜性肾病(IMN)是老年人肾病综合征的主要病因。由于老年患者的特殊性,特发性膜性肾病的治疗极具挑战性。本研究旨在探讨老年特发性膜性肾病的临床病理特征和初始治疗效果。

方法

回顾性分析 2016 年至 2020 年广东省人民医院经肾活检证实的 67 例特发性膜性肾病老年患者(58.2%为男性,中位年龄 69.0 岁,范围 65-83 岁)的临床病理资料和初始治疗效果。

结果

67 例患者的平均 eGFR 为 66.49ml/min/1.73m,尿蛋白/肌酐比值(uPCR)和尿白蛋白/肌酐比值(uACR)的中位数分别为 5676.73mg/g 和 2951.56mg/g。病理数据显示膜性 Churg's Ⅱ期最常见(71.64%)。此外,所有患者中 PLA2R 抗原肾小球荧光强度(+)和 IgG4 抗原肾小球荧光强度(++)分别为 63.6%和 86.4%。总体而言,44 例(65.7%)患者在肾活检后 1 年内达到缓解,包括完全缓解和部分缓解。与未缓解组相比,缓解组 uPCR(6274.6 vs. 3235.6mg/g,=0.007)和 uACR(3433.6 vs. 1773.2mg/g,=0.017)水平显著升高。缓解组接受免疫抑制治疗的比例也较高(86.4% vs. 30.4%,<0.01)。与保守治疗相比,联合应用糖皮质激素和环磷酰胺(CTX)或糖皮质激素和钙调神经磷酸酶抑制剂(CNIs)的患者缓解率更高(糖皮质激素加环磷酰胺与保守治疗相比,84.6% vs. 27.3%,=0.001;糖皮质激素加钙调神经磷酸酶抑制剂与保守治疗相比,88.0% vs. 27.3%,<0.001)。进一步分析表明,与保守治疗组相比,联合应用糖皮质激素和 CTX 组的男性比例、uPCR、uACR、BUN、Scr、CysC 和肾活检 PLA2R 抗原阳性染色率较高,而 eGFR、TP 和 ALB 水平较低(<0.05)。此外,与保守治疗相比,联合应用糖皮质激素和 CNIs 的患者 uPCR、uACR、TC 水平较高,TP、ALB 水平较低(<0.05)。此外,免疫抑制治疗组和保守治疗组在 eGFR 1 年进展率方面无统计学差异(3.3 vs. 0.2ml/min/1.73m,=0.852)。

结论

大多数诊断为 IMN 的老年患者合并多种合并症,膜性 Churg's Ⅱ期最常见。肾小球 PLA2R 和 IgG4 抗原沉积常伴有肾小球硬化和严重肾小管间质损伤。对于蛋白尿严重的高危老年患者,早期初始免疫抑制治疗可提高尿蛋白缓解率。因此,临床医生应根据临床和病理特征权衡免疫抑制治疗的风险和益处,为老年特发性膜性肾病患者制定个体化治疗方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30df/10193915/2a6506f795ee/IRNF_A_2212081_F0001_B.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验